Parker JA - Search Results

1

Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism.

Wolfe MW, Lee RT, Feldstein ML, Parker JA, Come PC, Goldhaber SZ. Wolfe MW, et al. Among authors: parker ja. Am Heart J. 1994 May;127(5):1371-5. doi: 10.1016/0002-8703(94)90058-2. Am Heart J. 1994. PMID: 8172067

2

Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.

Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, et al. Goldhaber SZ, et al. Among authors: parker ja. Lancet. 1993 Feb 27;341(8844):507-11. doi: 10.1016/0140-6736(93)90274-k. Lancet. 1993. PMID: 8094768 Clinical Trial.

3

Tissue plasminogen activator and acute pulmonary embolism.

Goldhaber SZ, Kessler CM, Heit J, Markis JE, Sharma GV, Dawley DL, Meyerovitz MF, Vaughan DE, Parker JA, Come PC, et al. Goldhaber SZ, et al. Among authors: parker ja. J Cell Biochem. 1988 Dec;38(4):303-12. doi: 10.1002/jcb.240380409. J Cell Biochem. 1988. PMID: 3149283

4

Lung scan evaluation of thrombolytic therapy for pulmonary embolism.

Parker JA, Drum DE, Feldstein ML, Goldhaber SZ. Parker JA, et al. J Nucl Med. 1995 Mar;36(3):364-8. J Nucl Med. 1995. PMID: 7884495 Free article.

5

Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator.

Come PC, Kim D, Parker JA, Goldhaber SZ, Braunwald E, Markis JE. Come PC, et al. Among authors: parker ja. J Am Coll Cardiol. 1987 Nov;10(5):971-8. doi: 10.1016/s0735-1097(87)80333-9. J Am Coll Cardiol. 1987. PMID: 2959713 Free article.

6

Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.

Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Kanter DS, et al. Among authors: parker ja. Chest. 1997 May;111(5):1241-5. doi: 10.1378/chest.111.5.1241. Chest. 1997. PMID: 9149576 Clinical Trial.

7

Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.

Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Daniels LB, et al. Among authors: parker ja. Am J Cardiol. 1997 Jul 15;80(2):184-8. doi: 10.1016/s0002-9149(97)00315-9. Am J Cardiol. 1997. PMID: 9230156

8

Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis.

Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Mikkola KM, et al. Among authors: parker ja. Am Heart J. 1997 Jul;134(1):69-72. doi: 10.1016/s0002-8703(97)70108-x. Am Heart J. 1997. PMID: 9266785

9

Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.

Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Mikkola KM, et al. Among authors: parker ja. Am Heart J. 1997 Oct;134(4):603-7. doi: 10.1016/s0002-8703(97)70041-3. Am Heart J. 1997. PMID: 9351725

10

Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.

Parker JA, Markis JE, Palla A, Goldhaber SZ, Royal HD, Tumeh S, Kim D, Rustgi AK, Holman BL, Kolodny GM, et al. Parker JA, et al. Radiology. 1988 Feb;166(2):441-5. doi: 10.1148/radiology.166.2.3122266. Radiology. 1988. PMID: 3122266

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

447 results

Search Page